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An Adipoinductive Role of Inflammation
in Adipose Tissue Engineering: Key Factors
in the Early Development of Engineered Soft Tissues
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Richard Tee,2 Andreas Mo¨ller,5,6 Erik W. Thompson,3,7 and Keren M. Abberton2–4
Tissue engineering and cell implantation therapies are gaining popularity because of their potential to repair and
regenerate tissues and organs. To investigate the role of inflammatory cytokines in new tissue development in
engineered tissues, we have characterized the nature and timing of cell populations forming new adipose tissue
in a mouse tissue engineering chamber (TEC) and characterized the gene and protein expression of cytokines in
the newly developing tissues. EGFP-labeled bone marrow transplant mice and MacGreen mice were implanted
with TEC for periods ranging from 0.5 days to 6 weeks. Tissues were collected at various time points and
assessed for cytokine expression through ELISA and mRNA analysis or labeled for specific cell populations in
the TEC. Macrophage-derived factors, such as monocyte chemotactic protein-1 (MCP-1), appear to induce
adipogenesis by recruiting macrophages and bone marrow-derived precursor cells to the TEC at early time
points, with a second wave of nonbone marrow-derived progenitors. Gene expression analysis suggests that
TNFa, LCN-2, and Interleukin 1b are important in early stages of neo-adipogenesis. Increasing platelet-derived
growth factor and vascular endothelial cell growth factor expression at early time points correlates with pre-
adipocyte proliferation and induction of angiogenesis. This study provides new information about key elements
that are involved in early development of new adipose tissue.
Introduction
Adipose tissue engineering aims to produce new, stableadipose tissue for use in regenerative and aesthetic
medicine as an alternative to breast prosthesis postmastec-
tomy and to the current complex flap procedures used to treat
defects from trauma, burns, or tumor removal. Many of the
complications and morbidity associated with current options
could be avoided [1–3].
We have developed an in vivo mouse model that success-
fully generates new adipose tissue in a tissue engineering
chamber (TEC) containing the basement membrane-rich ex-
tract Matrigel [4–7]. Inflammation appears key to the process
of neo-adipogenesis, and Zymosan (Zy-A), a sterile inflam-
mation inducing yeast fragment, can stimulate spontaneous
adipose tissue in this model [8,9]. Fat tissue is an important
endocrine and signaling organ and to regulate physiologic
processes throughout the body by secreting adipokines [10]. In
addition, adipocyte precursors and macrophages are reported
to share similar functions [11–13]. Adipokines and cytokines
secreted by macrophages are involved the 3 crucial compo-
nents of adipose tissue growth and stability: adipogenesis,
angiogenesis, and matrix and scaffold remodeling. Monocyte
chemotactic protein-1 (MCP-1) and macrophage inflamma-
tory protein-1 alpha (MIP-1a), agents known to be secreted by
macrophages, are also secreted by preadipocytes [14].
Adipogenesis is controlled by a complex interplay be-
tween positive and negative regulators, which change the
activity of different transcription factors. Peroxisome
proliferator-activated receptor gamma (PPARg) and CCAAT/
enhancer-binding proteins (CEBP) have emerged as master
regulators of adipogenesis [15]. Activin-A and basic fibro-
blast growth factor (FGF2) have been shown to have critical
roles in preadipocyte proliferation in adipose tissue [16],
with Activin-A expression increased in the macrophages of
obese patients.
We hypothesized that a low level of inflammation can
induce adipogenesis, through promoting the mobilization of
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adipose precursor cells that home to the TEC, differentiating
to form new adipose tissue [8,9,17]. In order to further in-
vestigate the interplay between inflammation and adipo-
genesis, we have used our mouse TEC model to study the
type and timing of early cellular recruitment to the chamber,
and the cytokine profiles associated with these cells. Here we
show for the first time, using our unique TEC model, that
early cellular recruitment to the chamber is bone marrow
driven, whereas later waves of neo-adipogenesis are stromal
derived.
Materials and Methods
Implantation of mouse TECs
Animal experiments were approved by the St Vincent’s
Hospital Animal Ethics Committee or the Peter MacCallum
Cancer Centre Animal Ethics Committee and conformed to
the NHMRC guidelines. All mice used were male C57/BL6
mice, unless otherwise stated. TECs with an internal diam-
eter of 5· 3.35mm (44 mL volume) made from silicone tubing
(Dow-Corning Corp.) and placed on the right epigastric
pedicle as described previously [5,9]. The superficial epi-
gastric vessels were dissected free of surrounding tissue from
their origin at the femoral vessels to their insertion into the
groin fat pad. The chambers were split longitudinally on one
side and placed around the cleared epigastric vessels and
nerve. The proximal femoral end and the lateral split were
sealed with melted bone wax (Ethicon). The chamber was
then filled with Matrigel with or without Zymosan–A (Zy-A)
at a concentration of 1mg/mL (Sigma). The distal end of the
chamber was sealed with melted wax, creating a seal without
damaging the epigastric pedicle exiting the chamber and the
skin closed with metal staples. The TEC model was used as
the basis of the following experiments.
Confirmation of adipogenic potential of the model
Mouse TEC containing Matrigel with Zy-A were im-
planted into mice (n = 6) on one side of the groin, with
Matrigel-only (no Zy-A, no FGF2) controls implanted on the
other side to assess the inflammatory impact of the surgery
alone on the TEC. At 6 weeks postimplantation, the mice
were euthanized and the TEC and their contents harvested.
Tissues were fixed in 4% paraformaldehyde, dehydrated,
and paraffin-embedded. Each tissue construct was then se-
rially sectioned (5 mm sections) along its longitudinal axis,
mounted onto an APES treat glass slide, and stained with
hematoxylin and eosin following a standard histological
protocol and assessed using the Zeiss Axioskop 2 microscope
and photographed using an Axiocam MRc5digital camera
and Axiovision software (version 4.2).
Characterization of cytokine and adipokine protein
expression during the early stages of adipose tissue
development in (i) the TEC and (ii) peripheral
serum samples
Cytokine assessment by ELISA. Mice were implanted with
TEC containing Matrigel and Zy-A. Mice were euthanized
and chambers collected at 6 time points: 12 h and 1, 2, 4, 7,
and 10 days postimplantation (n = 8 per time point). Control
chambers were implanted and harvested at 12 h time point to
assess the immediate impact of implanting chambers with-
out the additional inflammatory stimulus of Zy-A.
Quantikine High Sensitivity ELISA kits (R&D Systems)
were used to assess MCP-1, MIP-1a MIF-1, interleukin
(IL)1b, IFNg, VEGF-A, platelet-derived growth factor
(PDGF), transforming growth factor-b (TGFb), FGF2, TNFa,
and IL-6. Serum samples were collected from each mouse at
harvest and diluted to 1mL total volume in PBS.
Chambers were macerated in 1mL PBS at 4C to re-liquefy
the Matrigel and centrifuged 10min, and the supernatant was
removed, stored at - 80C, and then transferred and stored at
4C during assay. Assays were performed as per manufac-
turer’s instructions. About 100mL of diluent was added to
each well of an antibody-coated plate, followed by 100mL of
sample from either macerated chambers or collected serum.
Plates were incubated for 2 h at room temperature (RT) and
rinsed 4 times with a wash buffer, and then the buffer was
removed and 200mL conjugate added. Plates were incubated
for a further 2 h at RT, rinsed 4 times, the buffer removed, and
200mL color substrate added. After incubating 30min in the
dark at RT, 50mL of stop solution was added to each well.
Plates were read using a Multiskan microplate reader (Path-
tech) set at l 450nm absorbance with a correction reading set
at l 550nm and analyzed using Genesis 2 plate-reading
software (version 3.04; Lifesciences) and values were calcu-
lated back to pg/mL of the original sample volume.
Characterization of cytokine and adipokine gene expression in
TEC during the early stages of adipose tissue development using
multiplex bead gene expression array. Mice were implanted
with TEC and harvested at 4 time points (n= 6 per time
point): 4, 7, 10, and 14 days postimplantation (insufficient
tissue is present at the previous earlier time points for these
experiments). QuantiGene Plex (QGP; Panomics) assays were
used to examine the expression of the following genes in the
TEC: MCP-1, TNFa, IL1b, IL4, IL10, MIF, CEBPa, CEBPb, NF-
kB1, NF-kB2, LCN-2, Leptin, FABP4, and PPARg.
Following harvest at 4, 7, and 10 days, TEC contents were
placed in RNALater (Ambion), stored for 24h at 4C, and then
processed using the Panomics Tissue Lysis kit. Following
centrifugation, RNALater was replaced with 300mL of lysis
reagent. Tissue was disrupted with a Microson Ultrasonic
Homogeniser until only small tissue particles remained. Pro-
teinase K (stock concentration 50mg/mL) was added at a ratio
of 1:100 to the lysis mixture. Samples were incubated for 45min
at 65C and vortexed every 15min. QGP procedure for tran-
script analysis has been described elsewhere [18,19]. Mouse
Universal RNA was added to each plate for normalization.
Fluorescent bead signal was obtained using BioPlex Sus-
pension Array System (Bio-Rad Laboratories). Fluorescent
intensity of the gene of interest was normalized to 2 reference
genes. For comparison between multiple plates, data were
normalized using mouse universal RNA. Each sample was
run in triplicate with 6 different samples per group. The 2
sets of data obtained were similar using either PPIB or HPRT
as the reference gene; we have presented the data set using
HPRT as a reference.
Culture of the TEC contents for identification
of cells tracking to the chamber
Cell culture of chamber contents. To study the cells that
home to the TEC, chambers were harvested at corresponding
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points [12 h, and 1, 2, 4, 7, and 10 days postimplantation
(n = 8 per time point)] to those chosen for cytokine analysis.
The vascular pedicle was removed and chamber contents
digested using Collagenase I (Sigma) and Dispase (Invitro-
gen). The cells were then cultured in BD Falcon 8-well Cul-
tureSlides (BD Biosciences) in DMEM (Invitrogen) with 10%
FCS and antibiotics for 3 days at 37C for 3 days before
removing media and fixing with ice-cold acetone for 10min.
Immunocytochemistry. Macrophages were detected using
rat anti-mouse F4/80 monoclonal antibody (Abcam), which
labels a cell-surface glycoprotein expressed by murine mac-
rophages. To localize STRO-1, a cell surface marker of mes-
enchymal progenitor cells, a mouse anti-human STRO-1
monoclonal antibody, was used (R&D Systems, Inc.). Pref-1,
a transmembrane protein expressed in preadipocytes but not
in mature adipocytes, was detected using rat anti-mouse
anti-Pref-1 purchased from MBL International. Mouse anti-
human alpha-smooth muscle actin (aSMA) antibody, used to
label smooth muscle cells, was purchased from Dako. As a
secondary antibody, rabbit anti-rat IgG-biotin (Dako), was
used for F4/80 and Pref-1 antibodies, goat antimouse IgM-
biotin for anti-STRO-1 (Southern Biotech), and Dako mouse
envision for aSMA. For negative controls, primary anti-
bodies were replaced by either diluent alone or a matched
isotype nonimmune serum. Primary cultures of mouse SVF,
mouse smooth muscle cells, and commercial RAW 264.7
macrophages were used as positive controls for STRO-1 and
Pref-1, aSMA, and F4/80.
Slides were washed with PBS and incubated in Peroxidase
block for 5min and then in protein block for 30min. Dako
Protein block was used for aSMA, 20% normal goat serum
for STRO-1, and 10% normal rabbit serum in PBS for Pref-1
and F4/80. After blotting, sections were incubated with
primary antibody for 1 h. Dilutions using PBS were 1:100
with 20% normal goat serum for STRO-1, and 1:100 and
1:200 with normal rabbit serum for Pref-1 and F4/80, re-
spectively. For aSMA, primary antibody was diluted 1:400 in
Dako antibody diluent and Dako mouse Envision was used
for detection. For the other antibodies, after PBS washing
sections were incubated with goat anti-mouse IgM-biotin for
STRO-1, and with rabbit anti-rat IgG-biotin for F4/80 and
Pref-1 for 30min. Detection was completed with a strepta-
vidin-horseradish peroxidase conjugate and liquid DAB
chromagen (Dako) for all antibodies, followed by counter-
staining with hematoxylin. All reactions took place at RT.
Slides were scored by 2 independent observers using the
Zeiss Axioskop 2 microscope and photographed using an
Axiocam MRc5digital camera and Axiovision software
(version 4.2).
In vitro cell differentiation with adipogenic media. To con-
firm that the cells homing to the chamber at early time
points included adipose progenitor cells, the contents of 2
further sets of TEC at the 4 and 10 day time points. The cells
were then extracted as described previously and cultured on
tissue culture coverslips at 37C with 5% CO2 until 75%
confluent, and then seeded into 90mL culture flasks, and
cultured with adipose differentiation media [20] or standard
growth media and incubated for 14 days. Cells were fixed
using neutral buffered formalin, stained with Oil Red O,
and counterstained with hematoxylin. Cultures were pho-
tographed on an Olympus CK40 and Camedia C-5050
camera.
Identification of the source of precursor cells
in the chamber
Immunofluorescence labeling. In order to determine whe-
ther the cells forming the new adipose tissue were recruited
from BMSC or elsewhere, we established chambers in male
C57/Bl6 mice that had been transplanted with eGFP-labeled
bone marrow as described previously [21]. Briefly, recipient
mice were lethally irradiated before receiving eGFP-positive
bone marrow from NZ-eGFP donor mice. Positive reconsti-
tution (above 95%) was confirmed 6 weeks later by flow
cytometry. TEC were implanted as described above and
harvested at 3 time points t 4 days, 2 weeks, and 6 weeks
(n= 5 per group).
Four-day samples that contained cells rather than tissue
were rapidly pipetted up and down in PBS, creating a cell
suspension. Cell suspensions were placed on positively
charged slides and cells were allowed to adhere in a mono-
layer for 30min and then fixed with cold acetone for 10min.
For double immunostaining of Stro-1 and GFP, slides were
washed with TBS and incubated for 10min in 0.3% Triton
X100 for permeabilization, and then incubated in 20% goat
serum block for 30min. After blotting, cells were incubated
with 1:100 Stro-1 at 4C overnight. Further incubation was
carried out with 1:200 goat anti-mouse IgM-biotin (South-
ernBiotech; 1021-08), with 1:400 streptavidin-Alexa Fluor 488
(Molecular Probe, Inc.) for 30min in the dark, with GFP
antibody (Abcam ab290) for 1 h at RT in the dark, and then
with 1–200 cy3 goat anti-rabbit IgG for 30min and counter-
stained with DAPI in prolong gold (Invitrogen).
Two- and 6-week chamber specimens were fixed over-
night at 4C in 4% paraformaldehyde. The tissue was then
embedded in paraffin and cut into 5-mm sections for im-
munostaining of NG2/GFP, CD31/GFP, F480/GFP, and
NG2/S-100 Rabbit polyclonal antibody to NG2 [1:1,000 di-
lution at a final concentration of 1 mg/mL (Abcam; ab87471)],
rabbit polyclonal antibody to GFP [1:1,000 dilution (Abcam;
ab290)], rabbit anti-cow S100 [at 4.1 mg/mL (DAKO; Z0311)],
rat anti-mouse CD31 [at 3.1 mg/mL (BD Pharmingen)], and
rat anti-mouse F480 (at 2 mg/mL) were the primary anti-
bodies. In negative controls for individual antibodies, the
primary antibody was replaced with an irrelevant antibody
at the same concentration as the primary. Sections were
labeled following Double Staining Protocol—Sequential
Approach for Primary Antibodies Raised from Same Species
(www.ihcworld.com). Normal rabbit serum was used to
block free binding sites of the anti—rabbit immunoglobulin
before the 2nd primary antibody was added, and nega-
tive controls were run with buffer replacing the primary
antibodies. Alexa Fluor 488 goat anti-rabbit IgG and Cy3
goat anti-rabbit IgG secondary antibodies were used. For
CD31 and F480, rabbit anti-rat IgG biotin (DAKO; E0468)
secondary antibodies were incubated with Alexa Fluor 488
streptavidin.
Statistical analysis
Statistical analyses were performed using Prism V5.04 soft-
ware (Graphpad Software, Inc.). Results were compared using
analysis of variance, with a post hoc Bonferroni test where
appropriate. P values< 0.05 were considered statistically sig-
nificant. Standard errors (– ) of means are given throughout.
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Results
Confirmation of adipogenic potential of the model
Chambers initiated with Zy-A harvested at 6 weeks con-
tained significant amounts of mature adipose tissue (Fig. 1),
confirming the inflammation-induced adipogenic response
previously reported [9].
Characterization of cytokine and adipokine
expression in chambers and systemically
Local TEC expression. MCP-1 and MIP-1a (Fig. 2b, C)
were highly expressed by cells in the chambers between days
0.5 and 2.: MIP-1a expression is significantly elevated com-
pared to controls at D0.5 and D1 (P < 0.05), while MCP-1
expression is high for D0.5-D2, but has significantly de-
creased byD10 (P £ 0.05), coinciding with the large numbers
of macrophages cultured from the chamber at these time
points. Levels of macrophage migration inhibitory factor 1
(MIF-1) protein increased slightly from days 4–10 (data not
shown), while mRNA levels were high at days 4–7 and de-
creased slightly at day 10 (Fig. 3f).
The transcription factor, CEBPb expression remained
consistently high in the chamber, showing increased ex-
pression at day 7, dropping at day 10, and then increasing
again at 2 weeks (Fig. 3a). Although these changes were not
significant (P = 0.059), they are reflected in significant in-
creases in gene expression at day 7 for the CEBPb-mediated
cytokines IL1b and TNFa and the glycoprotein LCN-2
(P = 0.0001 for each factor), all of which decrease by day 10
(Fig.3b–d) and increase at 2 weeks after implantation. This
pattern is also seen in Mif-1 expression (Fig. 3e). IL1b and
TNFa levels were shown to be increasing from day 4 toward
day 10 (Fig. 2d, e). IL1b protein expression was 100-fold
higher than TNFa, while mRNA expression was 10-fold
higher. IL1b protein expression appears to be biphasic as
expression was high immediately after surgery, dropping at
day 2 then increasing over days 7–10 (Fig. 2d). In contrast,
TNFa expression increased from day 7 (Fig. 2e). IL6 protein
levels were elevated from 0.5 to 2 days and decreased from
days 7 to 10, but was not increased compared to the surgery
alone controls (Fig. 2a). IFNg was not observed in the TEC.
Nuclear factor kappa-light-chain-enhancer of activated B
cells (NFkB)-1 expression was consistent from days 4 to 10,
increasing slightly at 2 weeks, while NFkB-2 expression in-
creased at days 7 and 14.
Anti-inflammatory/adipogenic related expression. PPARg,
expression which is also induced by CEBPb, was signifi-
cantly increased (P = 0.013) at 2 weeks compared to earlier
time points in the chamber (Fig. 3h). NFkB (a PPARg an-
tagonist) expression was 25–50 times higher (Fig. 3j, k) than
PPARg at this time but showed a similar pattern of expres-
sion, with increases at the 2 week time point. Expression of
CEBPa and FABP-4 (P = 0.015), which are both induced by
PPARg, were also increased at 2 weeks (Fig. 3g, i). The lowest
level of expression for all of these factors occurs at day 7,
which is the time point when inflammatory mediators IL1b
and TNFa expression were highest (Fig. 3b, c). Leptin and
the alternatively activated macrophage markers IL4 and IL10
mRNA expression did not change significantly during the 4
day to 2-week time course (data not shown).
Growth factor expression. PDGF levels in the chamber re-
mained constant with a brief increase around days 1–2. Vas-
cular endothelial cell growth factor (VEGF-A) levelswere quite
high (1–2ng/mL) with an increase in VEGF-A secretion at
days 4–7, dropping at 10 days (Fig. 2f, g). Transforming growth
factor-b (TGFb1) levels remained constant throughout the time
points studied (Fig. 2i). FGF2, levels which have been sup-
plemented in the chamber, were extremely high, but showed a
significant drop at day 4, indicating that unbound FGF-2 was
being dissipated (Fig. 2h).
Systemic inflammatory cytokine expression. Serum FGF-2
levels are significantly lower in controls and at D0.5 (P£0.05),
PDGF, which is measured at significantly higher levels than
other cytokines (here expression in nanograms, while all other
cytokines measured in picograms). VEGF-A levels, FGF-2,
PDGF, and VEGF levels all appear to increase around day 2
(Fig. 4b–d), Circulating levels of all inflammatory cytokines
measured remained low throughout all time points. Circulating
levels of MCP-1 (Fig. 4a) showed an increase immediately after
surgery in the Zy-A mice compared to controls at D0.5, which
decreases by D10 (*P£0.05), (Fig. 4a), while circulating levels of
MIP-1a were not significantly increased. IL-6 levels show a
transient increase in expression at D2 which decreases by D4
(P£0.01) (Fig. 4e, f). These spikes were seen at the same time as
increases in growth factor expression were observed in serum.
Circulating levels of IL-1b and TNF-a did not show a signifi-
cant change across these time points (Fig. 4g, h).
FIG. 1. Confirmation of the adipogenic tissue engineering chamber (TEC) model. (a) Representative tissue construct har-
vested from the TEC at 6 weeks postimplantation, showing that the chamber is almost filled with adipose tissue. (b) High
power image of the tissue showing healthy fat developing, with some Matrigel fragments remaining. Scale as marked. n = 6.
Color images available online at www.liebertpub.com/scd
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Identification of cells tracking to the chamber
Cell migration and immunocytochemistry. The first cell
population that arrived at the chamber were F4/80-positive
macrophages (Fig. 5a). The size and number of F4/80-
positive macrophage increased toward day 7, as these cells
internalize Zy-A particles and more migrate into the cham-
ber. From day 7, we observed an increase of different cell
types and overall cell numbers within the chambers: F4/80-
positive macrophages, aSMA-positive cells that are probably
myofibroblasts (Fig. 5b), a small number of Pref-1 (adipose
precursor cells) and STRO-1-labeled cells (MSC) were seen
(Fig. 5c, d). Potential adipose precursor numbers in the
chamber by 10 days were estimated at 0.5%–1% of the total
cell population.
In vitro differentiation of the cells harvested from TEC. Cells
from TEC harvested at days 2, 4, and 10 were expanded in
culture with adipoinductive media for 14 days. Day 2 and 4
time points were chosen based on the changes seen in cy-
tokine expression while day 10 was chosen as the time point
when the most cells were present. Cells containing lipid
droplets were observed in all cultures, with*1% of the cells
differentiating into new adipocytes (Fig. 5f).
Immunofluorescence staining of eGFP bone marrow-trans-
planted mice chambers. To determine the origin of the cells
infiltrating the chambers, we generated eGFP-bone marrow
chimeras. In these mice, all bone-marrow-derived cells are
identifiable by their eGFP expression in immunofluores-
cence. We found that all of the cells in the chambers after 4
days were eGFP positive, indicating that their bone marrow
origin. The majority of the cells present were macrophages
(F480 positive, Fig. 6a), with a small number of neutrophils
as assessed by morphology. Some cells were STRO-1 posi-
tive, suggesting that they were MSC. eGFP-positive cells
FIG. 2. Protein levels of cytokines/growth factors in the TEC as measured by ELISA. (a) Interleukin (IL)-6 expression is
significantly lower by D10 than all other time points (*P £ 0.05). (b) Macrophage inflammatory protein-1 alpha (MIP-1a)
expression is significantly evaluated compared to controls at D0.5 and D1 (*P < 0.05) but has decreased by D2. (c) Monocyte
chemotactic protein-1 (MCP-1) expression. MCP-1 expression is high for D0.5–D2, but has significantly decreased byD10
(*P £ 0.05) suggesting that inflammation is being resolved, while both (d) IL-1b levels are significantly higher than controls by
D2 (*P £ 0.05) and demonstrate a biphasic response as seen in (e) TNFa. (f) Vascular endothelial cell growth factor (VEGF)
levels in the chamber remain high, with an increase in expression around day 4 that may relate to preadipocyte proliferation.
(g) Platelet-derived growth factor (PDGF) expression in the chamber is significantly lower than systemic expression (refer Fig.
3C). (h) FGF-2 expression showing a significant decrease at D7 (*P £ 0.001). (i) Transforming growth factor-b (TGF-b) ex-
pression continues to increase throughout the time course. All groups n = 4.
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were still evident in the construct after 6 weeks as adipocytes,
especially young adipocytes (Fig. 6b, c); however, no STRO-1-
positive cells were seen at this time. Both immature and adult
adipocytes stained positive for NG2 and s100 although NG2
labeling was more consistent than s100 (Fig. 6d). At 2 weeks
CD31 + endothelial cells can be seen invading the chamber
(Fig. 6e, f). Some CD31-labeled endothelial cells were eGFP
positive, but most endothelial cells are negative for eGFP,
indicating that they are derived from local vessels. Associated
with these newly forming vessels was a population of extra
mural cells that were positive for NG-2 and S100. The results
indicate that early precursor cells in the chamber are derived
fromBMSC,with furthermigration of precursor cells from the
surrounding tissue occurring at around 14 days, at the same
time as increased expression levels of inflammatory cytokines
are seen in the chamber.
Discussion
Studies in obesity and metabolic syndrome have shown
that inflammation and adipogenesis are closely interrelated,
with adipocytes and inflammatory cells sharing receptors for
and secreting cytokines such as TNFa, IL1b, MCP-1, and
TGFb. Here we have investigated the early stages of adipose
tissue formation in the chamber in response to this inflam-
matory stimulus, with a particular emphasis on the role of
cells recruited from the bone marrow.
Macrophages entered the TEC as early as 12 h postinser-
tion. This led to an immediate increase in MCP-1 and MIP 1a,
with MIF levels increasing by day 4 providing a signal for
more macrophages to enter the TEC. These cytokines appear
to attract precursor cells such as MSC to the chamber to
support tissue development. Cytokine levels begin decreas-
ing in the chamber between days 2 and 4, while growth
factor expression increases, suggesting an alteration in mac-
rophage activation, as these are the main cell type in the
chamber and presumably the source of the increased growth
factors. These factors provide an additional stimulus for a
more varied influx of cells into the chamber and promote
new blood vessel formation. This step appears to be critical
for tissue development in this model, as work from our
laboratory looking at later time points than this study, has
shown that preventing macrophages from entering the
chamber through the addition of clodronate liposomes to the
TECs prevents tissue growth in the chamber The exclusion of
macrophages from the TEC results in a poorly defined
acellular construct with severely reduced angiogenesis and
adipogenesis (Debels et al., submitted). In combination with
the findings from the earlier time points in this study, this
suggests that macrophages and the cytokines they secrete
play a key role in tissue formation in the TEC.
The main increases in circulating cytokine expression post
insertion of the TEC were seen in MCP-1 and MIP-1a. Both
are chemotaxic for macrophages and lead to upregulation of
FIG. 3. Gene expression of cytokines and transcription factors in the TEC. Significant increases in expression of (a) CCAAT/
enhancer-binding proteins (CEBP)b and the CEBPb-mediated cytokines (b) TNFa (*P = 0.0001), (c) IL-1b (*P= 0.0001), and (d)
LCN (*P = 0.0001), can be seen at day 7, similar to the ELISA results. (e) MIF-1 expression, (f) MCP-1 expression. By day10,
expression of (g) CEBPA, (h) Peroxisome proliferator-activated receptor gamma (PPARg) (*P = 0.013), and (i) FABP4
(*P = 0.015), have increased while the inflammatory cytokines have decreased, although NFkB 1 and 2 show increases in
expression at days 7 and 14 (j, k). All groups n = 6.
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IL6. These factors also activate other white blood cell types
and increase circulating activated macrophages. Once this
inflammatory expression pattern is established in the body, it
could then lead to a similar pattern of inflammation and
attraction of precursor cells, and then downregulation at a
site outside the TEC. Increases in circulating VEGF-A, FGF-2,
and PDGF can be seen on days 1–2 postimplantation of TEC,
decreasing at day 4. These cytokines are secreted by mac-
rophages and endothelial cells and would be instrumental in
establishing the local microvasculature and are involved in
preadipocyte proliferation [22–26].
This study also correlates with previous work from our
institute (Rophael et al.) where combinations of the growth
factors VEGF, FGF2, and PDGF synergistically enhanced
angiogenesis and adipogenesis in the TEC. This was due to a
significant increase in cell infiltrate at 2 weeks consisting of
mesenchyme-derived cells such as macrophages pericytes
and adipose progenitor cells.ie an increased inflammatory
response. The current study looks at the earlier mechanisms
behind this cellular increase and demonstrates an increase in
the angiogenic/adipogenic PDGF and VEGF caused by the
inflammatory stimulus, suggesting that the addition of
growth factors in the previous study was mimicking this
response. A moderate inflammatory stimulus was sufficient
to draw in the same cells as were seen in the chamber at the 2
week point in the Rophael study as shown by successful
labeling of progenitor cells in the chamber and the explanted
chamber contents leading to adipogenesis/angiogenesis
without adding exogenous growth factors, which may be a
concern in some clinical applications such as postcancer re-
construction.
Potential adipose precursor cells can be identified by 4
days postimplantation. These cells make up only a small
population (0.5%–1%) of the cells observed in the chambers
at this time; however, culturing the cells in vitro shows that
they are capable of adipogenesis. While there has been some
debate about whether STRO-1 can be labeled on mouse
BMSC, several groups have demonstrated STRO-1 labeling
in mouse cells, supporting our use of this marker to identify
MSC [27–30]. In our study, the STRO-1-positive cells and
FIG. 4. Systemic expression of cytokines as measured by ELISA (a) MCP-1 levels show a spike at D0.5, which decreases by
D10 (*P£ 0.05), (b) FGF-2 levels are significantly lower in controls and at D0.5 (*P£ 0.05), and (c) PDGF, which is measured at
significantly higher levels than other cytokines (here expression in nanogams while all other cytokines measured in pico-
grams). (d) VEGF-A levels. FGF-2, PDGF, and VEGF levels all appear to increase around day 2, (e) IL-6 show a transient
increase in expression at D2 which decreases by D4 (*P£ 0.01), and (f) MIP-1a. All groups n = 4. (g) IL-1B and (h) TNFa levels
showed no significant changes in expression over the time period measured.
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early stage macrophages can be shown to originate from the
bone marrow of the mice, indicating that the first cellular
response (0–4 days) is a systemic response and not from the
surrounding local tissues. BMSC have been shown to possess
multiple TLR and regulate cytokine signaling through TLR-2
activation—the same receptor that Zy-A binds to. Among the
TLR identified, TLR-2, -3, and -4 seem to be most critical
receptors upregulated by inflammation. TLR-2 receptors are
activated by Zy-A and upregulate MCP-1, a cytokine that is
significantly upregulated in the TEC, while TNF-a, which is
also upregulated, can also upregulate TLR-2 expression.
TLR-4 receptors upregulate IL6 and MIF to induce moderate
MSC migration [31,32]. Endogenous ligands have been
identified to TLR4 including heparin sulfate fragments and
HSPG, fibrinogen and fibronectin [33,34], which are present
in the Matrigel [35] in the chamber and could be cleaved
either by macrophage driven proteolysis or in response to
the inflammatory stimulus. High-mobility group box 1,
which is secreted by inflammatory macrophages [36] is an-
other potential ligand for TLR4 in the chamber. This may
explain why the BMSC can be found in chambers at early
time points postimplantation, attracted to the chambers by
the factors secreted by macrophages and the Zy-A present in
the chamber; however, no adipogenic differentiation is seen
until further resolution of inflammation. This may be further
influenced by macrophage produced Activin-A, which also
inhibits adipogenic differentiation of adipose precursor cells
while increasing proliferation [16,31] and is also under the
control of IL6/TNFa. The 5-fold increase in MIF expression
at 2 weeks may be responsible for the migration of a new
wave of MSC into the chamber, supplementing the expres-
sion of TNFa and IL1b, as MCP-1 and IL6 have been down
regulated by this time point.
After 10–14 days, new blood vessels can be seen infil-
trating the chamber, preceded by macrophages, in a similar
fashion to those seen by in Matrigel plugs [37,38]. These
vessels are predominantly GFP negative, indicating that they
have arisen from existing blood vessels rather than progen-
itor cells in the bone marrow. Some GFP-positive endothelial
cells can be seen integrated into the vessels, indicating that
some bone marrow-derived progenitors have formed part of
the endothelium. These vessels are associated with pericyte-
like cells that stain positively for S100 and NG2. At 6 weeks,
NG2-positive cells can be seen differentiating into adipocytes
while still adjacent to blood vessels. Pericytes have been
previously suggested to be putative adipose precursor/stem
cells with work by showing putative adipose precursor/stem
cells clearly surrounding vessels in the extramural space [39–
FIG. 5. Cell types identified
by immunocytochemistry in
the TEC contents in culture.
Chambers were harvested at
day 10 postimplantation. (a)
Macrophages, the most abun-
dant cell in the early TEC,
labeled with F480. (b) Myofi-
broblasts labeled with alpha-
smoothmuscle actin. (c) STRO-
1-positive cells identified in the
TEC. (d) Pref-1-positive pre-
adipocytes. (e) High magnifi-
cation image of a macrophage
full of Zy-A particles. (f) Cells
cultured from a TEC chamber
on day 10 demonstrating adi-
pogenic potential as shown by
Oil-Red-o staining (red) of lipid
droplets. a–d: scale bar as
marked on c. e: scale bar as
marked. f: times 40 magnifica-
tion. Color images available
online at www.liebertpub
.com/scd
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42], as well as a study by Khan that identified the pericyte
marker 3G5 on adipose stem cells in the human infrapatellar
fat pad [43]. To examine this possibility, we labeled sections
with NG2, a pericytes marker as well as s100. Both NG2 and
s100 co-localized in some adipocytes as well as a population
of extramural cells surrounding the vasculature at 2 and 6
weeks.
Not all of the newly formed fat is GFP or s100 positive,
while the majority of adipocytes appeared to label for NG2.
However, eGFP labeling is present in many of the younger
adipocytes and these cells are most likely to arise from the
population of GFP +/STRO-1 + cells seen in the day 4
chambers, correlating with the STRO-1 and Pref-1 popula-
tions seen in cells cultured in vitro from TEC. It is possible
that we have 2 sources of adipose progenitor cells in the TE
chamber model: (1) BMSC that are attracted to the chamber
by inflammatory cytokines acting through TLR and (2) a
second wave of adipose precursor cells that arrive with the
new blood vessels invading the TEC construct.
Reports of the effects of macrophages and macrophage-
secreted factors on adipogenesis have been varied. While we
have previously shown MCP-1 induction of adipogenesis in
TEC initiated by MCP-1 is dose dependent, Lacasa et al.
suggested that macrophage-secreted factors inhibit adipo-
genesis [24,44]. This would tie in with the changes we see in
NFkb expression at the times when cell numbers are in-
creasing in our chambers. Zaragosi et al. [16] have shown
that activin-A induces adipose progenitor cell proliferation
and migration. Activin-A is induced by TNF-a and IL1b and
acts in turn to down regulate CEBPb, paving the way for
differentiation into adipocytes. These factors may also attract
precursor cells from the bone marrow to the chamber to
initiate tissue development.
One way an increase in macrophages could lead to
neoadipogenesis is through an increase in the transcription
factor CEBPb expression, which regulates the expression of
IL6, IL1b, TNF-a, and Lcn2. These factors regulate or are
regulated by Activin-A [44,45] and NFkB. CEBPb expression
also upregulates PPARg, which upregulates adipogenesis
directly through the Wnt pathway (Fig. 7) PPARg and NFkB
are mutually antagonistic and as PPARg expression in-
creases, NFkB expression decreases, and the inflammation
begins to resolve. The newly recruited preadipocytes then
differentiate and adipogenesis occurs [17,46–50]. In contrast,
FIG. 6. Co-localization of
cell markerswith eGFP in TEC
from eGFP bone marrow chi-
meric mice. All sections are
counterstained with DAPI
(blue). (a) eGFP (green) and
F480 (red), a marker for mac-
rophages. (b) eGFP (green)
and S100 (red), a marker of
preadipocytes and adipo-
cytes. Colocalization can be
seen in yellow adipocytes
(arrow). (c) eGFP (green) and
NG2 (red), a marker for peri-
cytes that has been suggested
as a marker for putative adi-
pose precursor cells and also
labels adipocytes colocaliza-
tion can be seen in yellow
adipocytes (arrow). (d) s100
(green) and NG2 (red), show-
ing co-localization in young
adipocytes. Several cells
stained with s100 alone can
also be seen, possibly nerve
cells or macrophages. Yellow
staining indicates co-localiza-
tion. (e) eGFP (red) and CD31
(green), a marker for endothe-
lial cells. (f) Higher magnifi-
cation of part of image (e)
showing co-localization of
eGFP and CD31 in some
endothelial cells in the blood
vessels but not in all. Scale
as marked. Color images
available online at www
.liebertpub.com/scd
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recent work by Yonce et al. suggests that MCP-1 produced
by macrophages can induce adipogenesis through MCP-1-
induced protein (MCPIP) without direct PPARg initialization
in vitro [51], which may be an alternative pathway for
macrophage-induced adipogenesis in the chamber.
Of interest are the significant increases in expression of
CEBPb and the inflammatory cytokines regulated by this
transcription factor at day 7. This increase after inflammation
has begun to resolve may be due to the BMSC in the
chamber. While BMSC are mildly immunosuppressive, ac-
tivation of the TLR by factors such as Zy-A (TLR2 ligand),
and fibrinogen, fibronectin, and HSPG as potential TLR4
ligands in the chamber could lead in turn to the BMSC ex-
pressing CEBPb-driven factors and this may explain the bi-
phasic reactions we see in our gene and protein expression
assays. A second significant increase in expression of CEBPb
is seen at D14. MIF expression also increased, as did NFkB, a
mutual antagonist to PPARg, possibly due to the activation
of TLR-4. With the reduction of other inflammatory factors
and the increase adipogenic and growth related genes such
as PPARg, CEBPa, FABP4, and LCN-2, differentiation can be
induced and tissue growth occurs (Fig. 7).
Here we have provided a model for how new adipose
tissue growth is occurring, through adipose progenitor re-
cruitment and modulation of BMSC and macrophage activ-
ity. Understanding how inflammation can trigger adipose
recruitment and growth may give us new targets to fight
obesity, by blocking the action of TLR on macrophage and
BMSC signaling. From a tissue engineering perspective, we
can use this information to guide soft tissue reconstruction to
develop controllable stable adipose tissue for reconstructive
purposes.
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